Relations Prpa News Today

TOTUM•448 is an innovative plant-based patented active substance developed by Valbiotis, a young French SME, to counteract the development of metabolic liver diseases (NAFL and NASH1 In two

TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the

The last volunteer was enrolled in the REVERSE-IT study; recruitment of the 600 participants in this international, multicenter, randomized, placebo-controlled clinical study is complete. This

This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active